Effective Treatment of Neurogenic Detrusor Dysfunction by Combined High-Dosed Antimuscarinics without Increased Side-Effects

European Urology

Volumn 53, Issue 5, 2008, Pages 1021-1028

  Amend, Bastian ^a   Hennenlotter, Jörg ^a   Schäfer, Tobias ^a   Horstmann, Marcus ^a   Stenzl, Arnulf ^a   Sievert, Karl Dietrich ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Detrusor sphincter dyssynergia; Muscarinic antagonists; Neurogenic bladder; Oxybutynin; Side effects; Spinal cord injury; Tolterodine; Trospium

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; TOLTERODINE; TROSPIUM CHLORIDE;

ADULT; ARTICLE; BLADDER CAPACITY; BLADDER COMPLIANCE; BLADDER PRESSURE; BLURRED VISION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ENCEPHALOMYELITIS; FEMALE; FOLLOW UP; HUMAN; MALE; MENINGOMYELOCELE; MONOTHERAPY; MULTIPLE SCLEROSIS; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PATIENT SATISFACTION; PRIORITY JOURNAL; SPINAL CORD INJURY; TREATMENT OUTCOME; URINE INCONTINENCE; URODYNAMICS; XEROSTOMIA;

ADOLESCENT; ADULT; BENZHYDRYL COMPOUNDS; CRESOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MANDELIC ACIDS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; NORTROPANES; PARASYMPATHOLYTICS; PHENYLPROPANOLAMINE; SPINAL CORD DISEASES; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URODYNAMICS;

EID: 41149133817     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.01.007     Document Type: Article

References (33)

1. Abrams P., Cardozo L., Khoury S., and Wein A. Incontinence. 3rd ed. (2005), Health Publication Ltd pp. 1059-1162
2. Stohrer M., Castro-Diaz D., Chartier-Kastler E., et al. Guidelines on neurogenic lower urinary tract dysfunction. Prog Urol 17 (2007) 703-755
3. Stohrer M., Goepel M., Kondo A., et al. The standardization of terminology in neurogenic lower urinary tract dysfunction: with suggestions for diagnostic procedures. International Continence Society Standardization Committee. Neurourol Urodyn 18 (1999) 139-158
4. Chancellor M.B., Anderson R.U., and Boone T.B. Pharmacotherapy for neurogenic detrusor overactivity. Am J Phys Med Rehabil 85 (2006) 536-545
5. Madersbacher H. Oral anticholinergics in overactive bladder. Urologe A 45 (2006) 830-834
6. Van Kerrebroeck P.E., Amarenco G., Thuroff J.W., et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 17 (1998) 499-512
7. Van Kerrebroeck P., Kreder K., Jonas U., Zinner N., and Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57 (2001) 414-421
8. Appell R.A. The newer antimuscarinic drugs: bladder control with less dry mouth. Cleve Clin J Med 69 (2002) 761-769
9. Horstmann M., Schaefer T., Aguilar Y., Stenzl A., and Sievert K.D. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 25 (2006) 441-445
10. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
11. Staskin D.R., and MacDiarmid S.A. Using anticholinergics to treat overactive bladder: the issue of treatment tolerability. Am J Med 119 (2006) 9-15
12. Nitti V.W., Dmochowski R., Appell R.A., et al. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int 97 (2006) 1262-1266
13. Stöhrer M., Mürtz G., Kramer G., et al. Propiverine compared to oxybutynin in neurogenic detrusor overactivity-results of a randomized, double-blind, multicenter clinical study. Eur Urol 51 (2007) 235-242
14. Stohrer M., Bauer P., Giannetti B.M., et al. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. Urol Int 47 (1991) 138-143
15. Frohlich G., Bulitta M., and Strosser W. Trospium chloride in patients with detrusor overactivity: meta-analysis of placebo-controlled, randomized, double-blind, multi-center clinical trials on the efficacy and safety of 20 mg trospium chloride twice daily. Int J Clin Pharmacol Ther 40 (2002) 295-303
16. Appell R.A. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 50 (1997) 90-96 discussion 97-9
17. Menarini M., Del Popolo G., Di Benedetto P., et al. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients?. Int J Clin Pharmacol Ther 44 (2006) 623-632
18. Novara G., Galfano A., Ficarra V., and Artibani W. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 50 (2006) 675-683
19. Irani J. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: where do we stand in 2006?. Eur Urol 50 (2006) 653-654
20. Kaplan S.A., Roehrborn C.G., Rovner E.S., et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296 (2006) 2319-2328
21. Rosenzweig E.S., and McDonald J.W. Rodent models for treatment of spinal cord injury: research trends and progress toward useful repair. Curr Opin Neurol 17 (2004) 121-131
22. Chapple C.R., Yamanishi T., and Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology 60 (2002) 82-88 discussion 88-9
23. Andersson K.E. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 3 (2004) 46-53
24. Goepel M., and Steinwachs K.C. How do medications used to treat urinary incontinence affect the cerebral function of the elderly?. Urologe A 46 (2007) 387-392
25. Madersbacher H., Stohrer M., Richter R., et al. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 75 (1995) 452-456
26. Halaska M., Ralph G., Wiedemann A., et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 20 (2003) 392-399
27. Epstein B.J., Gums J.G., and Molina E. Newer agents for the management of overactive bladder. Am Fam Physician 74 (2006) 2061-2068
28. Hegde S.S. Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147 Suppl 2 (2006) S80-S87
29. Todorova A., Vonderheid-Guth B., and Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 41 (2001) 636-644
30. Ridder D.D. Antimuscarinics and cognitive function. Eur Urol 50 (2006) 211-212
31. Kay G., Crook T., Rekeda L., et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 50 (2006) 317-326
32. Patki P.S., Hamid R., Arumugam K., Shah P.J., and Craggs M. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 98 (2006) 77-82
33. Lazzeri M., and Spinelli M. The challenge of overactive bladder therapy: alternative to antimuscarinic agents. Int Braz J Urol 32 (2006) 620-630